At Oncopharm we are committed to delivering products of the highest quality. We believe that it is this commitment to excellence that sets us apart and allows us to deliver exceptional value to our patients and healthcare professionals.
Accordingly, we are thrilled to announce The Exciting News! Relaunching the well-known brand Valcyte® in the Egyptian market, after marketing authorization transfer from Roche to Cheplapharm Arzneimittel GmbH, through worldwide acquisition for the product, that’s definitely will help our physicians in the management of many cases who are susceptible to, or already suffering from cytomegalovirus.
